Introduction
============

Increasing dwell time of a central venous line is known to increase the risk of central line-associated bloodstream infection (CLABSI). Of late, substandard care of central lines because of the burden of workload has been identified as another risk factor.[@b1-idr-7-331] Prolonged use of broad-spectrum antibiotics[@b2-idr-7-331] has also been reported to predispose to CLABSI. However, the possible influence of antimicrobial use density (AUD) on CLABSI and the microbial susceptibility of isolates have seldom been investigated. In Japanese hospitals, a variety of classical antimicrobials are used, but their effect on CLABSI at the ward level has not been addressed, and the possible influence of AUD on CLABSI is unknown. AUD by ward and month may predict bloodstream infection in terms of space in the hospital and calendar time frames, respectively. In this study, we attempted to identify possible ways of preventing CLABSI, including AUD, by ward and month.

Materials and methods
=====================

Central lines and sites of insertion
------------------------------------

This retrospective study was performed in our 430-bed community hospital from March 2011 through February 2013. Midline catheters, including central venous and Swan-Ganz catheters, were inserted under maximum sterile barrier conditions. Povidone iodine solution (10%, Meiji Seika Pharma, Tokyo, Japan) was used as a skin antiseptic rather than 2% chlorhexidine, which was not commercially available in Japan. The infusion lines consisted of closed-hub systems that were disinfected using cotton swabs with 76.9--81.4 vol% ethanol (Yoshida Pharmaceuticals, Tokyo, Japan), as described previously.[@b3-idr-7-331] The central lines used were the CV Legaforce SX (Terumo Co, Tokyo, Japan) and the Arrow central venous catheter (Telefex Inc, Limerick, PA, USA), with a SurePlug infusion set (Terumo Co) for the hubs.

The site of central line insertion was covered with a sterile transparent dressing that was replaced every 7 days. When a patient developed a fever of more than 38.0°C, blood cultures were submitted; when possible, midline catheters were withdrawn and their tips were sent for culture. Although recommended by the Infectious Diseases Society of America,[@b2-idr-7-331] no blood cultures were drawn via the central line hubs. If the catheter was exchanged, continuous central line days were counted from 1 reduced from continuously counted line days.

Throughout the study period, infection control specialists inspected the wards weekly for compliance with techniques for prevention of contact infection and use of alcohol for hand hygiene. The central line infusates were prepared in the hospital pharmacy except in emergencies. Nurses on all wards were trained to inspect the sites of central line insertion in addition to monitoring body temperature in all patients. Thus, infection control measures were kept constant across the wards.

Regulation of antimicrobial use
-------------------------------

The infection control committee regulated agents targeting methicillin-resistant *Staphylococcus aureus* (MRSA) and broad-spectrum agents such as carbapenems, cefozopran, and cefepime. Otherwise, antimicrobials were administered at the discretion of the attending physicians. However, prophylactic use of agents for MRSA was only allowed on confirmation of MRSA by active surveillance culture prior to cardiovascular and orthopedic surgical procedures involving placement of an implant.

Definition of central line-associated bloodstream infection
-----------------------------------------------------------

We defined CLABSI in accordance with the definition of the Centers for Disease Control and Prevention.[@b4-idr-7-331] Thus, cases with infectious foci other than in the bloodstream were not identified as CLABSI and did not require central line withdrawal or replacement. Likewise, positive cultures from blood or other specimens in the presence of infectious foci other than in the bloodstream were not deemed to be CLABSI.

Definition of antimicrobial use density
---------------------------------------

The AUD was defined for 20 antimicrobials by ward and month as follows:
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where DDD is the daily dose as defined by the World Health Organization.[@b5-idr-7-331] The AUD data were averaged for the preceding month and for number of central line days in the analysis.

Susceptibility and its correlation with AUD
-------------------------------------------

Susceptibility of microbes isolated in CLABSI was defined according to the guideline of the Clinical and Laboratory Standards Institute (Wayne, PA, USA). For a given antimicrobial agent, the ratio of susceptible strains to all the strains was calculated and subjected to correlation analysis with the mean values of the corresponding AUD. Should only one strain have susceptibility for any drug, the ratio of susceptible strains was excluded from the analysis.

Definition of device utilization ratio
--------------------------------------

To evaluate the workload associated with use of a central line, the device utilization (DU) ratio[@b6-idr-7-331] was determined as follows for each ward:

DU ratio

=

Number of central line days/Patient days

where the time interval was from either March 2011 to February 2012 or March 2012 to February 2013.

Statistical analysis
--------------------

Into each item of data on central line day, we entered patient sex and age, the mean AUD for the month and the preceding month, the DU ratio, continuous days of central line placement, and presence or absence of CLABSI. To determine the optimal threshold for logistic regression analysis, a receiver-operating characteristic analysis was performed for continuous data, including central line days. We then performed a univariate logistic regression analysis of background factors for CLABSI, which was the outcome factor in this analysis. Statistical significance was determined as *P*\<0.05. Factors significant in the univariate analysis were subsequently tested by multivariate regression analysis. When *P*-values could not be determined because of sample deviation, those factors were excluded for further analysis. Statistical Package for the Social Sciences software (IBM Corporation, Armonk, NY, USA) was used for the statistical analysis.

Ethical considerations
----------------------

This study was approved by the internal review board at our institution. This decision was based on its compliance with the Ethical Guideline on Epidemiological Research (Revised April 1, 2013) issued by the Ministry of Education, Culture, Sports, Science, and Technology and by the Ministry of Health and Welfare, Japan.

Results
=======

Overview and clinical background
--------------------------------

Of a total of 9,997 line days over 24 months, CLABSI was present in 33 cases (3.3‰), 14 (42.4%) of which were in surgery ward out of a total of nine wards. Among the positive patients, eight (24.2%) had malignancy, eight (24.2%) had pneumonia, three (9.1%) had urinary tract infection, three (9.1%) had secondary peritonitis, two (6.1%) had joint infection, two (6.1%) had pancreatitis, two (6.1%) had vascular disease, and other diseases were present in five (15.2%) cases. These patients had received a variety of antimicrobials prior to the onset of CLABSI but none were given cefotiam ([Table 1](#t1-idr-7-331){ref-type="table"}). Prior to the episode of CLABSI with isolation of MRSA as described in the following, two patients had received vancomycin and one had received linezolid.

Bacterial isolates
------------------

Of 43 strains isolated as CLABSI, *S. aureus* accounted for ten cases (including eight MRSA strains), *Candida parapsilosis* for seven, *Enterobacter cloacae* for four, *Bacillus cereus* for three, *Enterococcus faecalis* for three, *Staphylococcus epidermidis* for three, *Candida glabrata* for two, *Staphylococcus caprae* for two, *Staphylococcus warneri* for two, and another seven species in one case each. No strains carried extended spectrum beta-lactamase.

Receiver-operating characteristic analysis
------------------------------------------

The receiver-operating characteristic analysis revealed central line day 7 had the highest accuracy. Univariate regression analysis showed significance in central line day and AUD of cefotiam. However, the ward factor, DU ratio, and others did not show statistical significance. Multivariate regression analysis showed central line day and AUD of cefotiam had an odds ratio of 5.511 (*P*\<0.001) and 0.220 (*P*=0.038), respectively.

Susceptible strain ratios and AUD
---------------------------------

A total of ten pairs of susceptible strain ratios and AUDs were subjected to correlation analysis, including ampicillin, cefazolin, cefmetazole, cefotaxime, cefotiam, clindamycin, flomoxef, fosfomycin, gentamicin, and imipenem/cilastatin. The pairs were inversely correlated, with *R*^2^=0.1897 ([Figure 1](#f1-idr-7-331){ref-type="fig"}). In seven strains tested for susceptibility to cefotiam, two (28.6%) were susceptible.

Discussion
==========

The current study shows that an increased AUD for cefotiam may help prevent CLABSI. The possible effect of ward-level antimicrobial pressure on CLABSI has not been addressed previously. To investigate this potential ward-specific effect, we used ward AUDs of various antimicrobials, in which cefotiam had significant odds ratio to decrease CLABSI. Nakamura et al[@b7-idr-7-331] reported that methicillin-resistant *S. epidermidis* isolated from blood culture and central lines had a low minimum inhibitory concentration for cefotiam. The definition of CLABSI would hardly permit *S. epidermidis* as a causative microbe but *S. epidermidis* remains as one of the major causes. Anecdotally cefotiam, not marketed in the USA,[@b8-idr-7-331] has seldom been described in the literature on bloodstream infection.

At the level of the individual patient, cefotiam was susceptible in a limited number of cases, thus precluding its empirical use[@b9-idr-7-331] in suspected cases of CLABSI. As regards MRSA, three of eight cases had received antimicrobial agents for MRSA but developed CLABSI, due probably to biofilm coated on the central line. At the ward level of antimicrobial use, however, less commonly prescribed antimicrobials may have a preventive effect on CLABSI.

A literature search for a possible relationship between AUD and CLABSI failed to yield similar studies. However, Meyer et al[@b10-idr-7-331] reported that increased AUDs for glycopeptides and quinolones showed increased hazard ratios with CL rates per 1,00 patient days in intensive care units in Germany. Kanerva et al[@b11-idr-7-331] proposed a patient case-mix adjustment model for antibiotic use in Finnish acute care hospitals, suggesting that use of central lines was not a significant risk factor in the model. Thus, correlation between ward-specific and month-specific AUD and CLABSI has rarely been addressed.

In Japan, Ikeda et al[@b12-idr-7-331] reported that a permission system for use of carbapenems reduced their AUD and the incidence of drug-resistant bacteria. Similarly, our study showed that AUDs were inversely correlated with susceptible strain ratios, indicating that increased use of any antimicrobial may decrease susceptibility for that particular drug. It has been reported that a prolonged duration of central line placement is a risk factor for CLABSI,[@b13-idr-7-331] and this was confirmed in the present study. Trick et al[@b14-idr-7-331] recommended that the need for a central line should be assessed on a day-by-day basis and that nursing staff should be encouraged to notify physicians of unnecessary central lines. The DU ratio was investigated as a possible risk factor for CLABSI, but no association was found. This may indicate that care at handling central lines was constantly observed regardless of the workload as represented by DU ratio. It has been suggested that male patient sex is a significant risk factor for CLABSI,[@b1-idr-7-331] but this was not the case in our study, and nor was being elderly.

The limitations of the present study are its retrospective design and the fact that the data are derived from a single institution. Another limitation is the lack of validation of computation of the background factor of AUDs averaging the reference and previous months for a central line day. Our findings require validation by further studies in the future.
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###### 

Antimicrobials given prior to the onset of central line-associated bloodstream infection (n=33 cases)

                                  Total dose (g)      Cases
  ------------------------------- ------------------- -----------------------------------------------
  Ampicillin-sulbactam            9 (7.5--10)         n=4
  Cefazolin                       6 (2--6)            n=3
  Cefmetazole                     24 (24)             n=1
  Cefoperazole-sulbactam          9 (8--10)           n=2
  Ceftazidime                     28 (2--38)          n=3
  Ceftriaxone                     6 (2--14)           n=3
  Ciprofloxacin                   0.6 (0.6)           n=1
  Clindamycin                     8.4 (8.4--8.4)      n=2
  Fluconazole                     1.0 (1.0)           n=1
  Flomoxef                        18 (8--28)          n=2
  Imipenem-cilastatin             3.5 (3.5)           n=1
  Levofloxacin                    6.0 (6.0)           n=1
  Linezolid                       17.6 (8.4--16.8)    n=2
  Meropenem                       5.5 (4--14)         n=5
  Minocycline                     8.4 (8.4)           n=1
  Piperacillin                    11 (4--14)          n=2
  Piperacillin-tazobactam         189 (189--189)      n=2
  Sulfamethoxazole/trimethoprim   16/3.2 (16)/(3.2)   n=1/1
  Teichoplanin                    12 (12)             n=1
  Vancomycin (parenteral)         1 (0.5--10)         n=3
  Subtotal                                            n=42[a](#tfn1-idr-7-331){ref-type="table-fn"}
  None                                                n=5[b](#tfn2-idr-7-331){ref-type="table-fn"}
  Total                                               n=47

**Notes:**

Twenty-eight cases had been administered a total of 42 antimicrobials permitting repetition;

five cases had received no antimicrobials prior to central line-associated bloodstream infection.

###### 

Logistic regression analyses on the risk factors for CLABSI, including ward-specific AUD of multiple agents

  Factor                     Univariate analysis                      *P*-value                                          Multivariate analysis   *P*-value
  -------------------------- ---------------------------------------- -------------------------------------------------- ----------------------- --------------------------------------------------
  AUDs                                                                                                                                           
   Ampicillin                0.26 (0.06--1.07)                        0.06                                                                       
   Ampicillin-sulbactam      0.70 (0.35--1.39)                        0.31                                                                       
   Cefazolin                 1.76 (0.88--3.55)                        0.11                                                                       
   Cefmetazole               0.69 (0.24--1.95)                        0.47                                                                       
   Ceftazidime               0.68 (0.33--1.41)                        0.31                                                                       
   Cefoperazole-sulbactam    1.46 (0.51--4.16)                        0.48                                                                       
   Cefotaxim                 1.14×10^−8^ (1.14×10^−8^--1.14×10^−8^)   N/A                                                                        
   Cefotiam                  0.21 (0.05--0.89)                        0.03[\*](#tfn3-idr-7-331){ref-type="table-fn"}     0.22 (0.05--0.92)       0.04[\*](#tfn3-idr-7-331){ref-type="table-fn"}
   Cefmetazole               0.69 (0.24--1.95)                        0.48                                                                       
   Cefozopran                0.73 (0.31--1.79)                        0.50                                                                       
   Cefpirome                 1.06×10^−7^ (1.06×10^−7^--1.06×10^−7^)   N/A                                                                        
   Ceftriaxone               0.41 (0.16--1.08)                        0.07                                                                       
   Clindamycin               0.62 (0.31--1.24)                        0.18                                                                       
   Flomoxef                  0.87 (0.43--1.74)                        0.68                                                                       
   Fosfomycin                1.01 (0.48--2.08)                        0.99                                                                       
   Gentamicin                1.34 (0.67--2.68)                        0.40                                                                       
   Imipenem-cilastatin       1.86 (0.83--4.13)                        0.13                                                                       
   Linezolid                 1.89 (0.95--3.76)                        0.07                                                                       
   Meropenem                 0.65 (0.30--1.39)                        0.26                                                                       
   Minocycline               1.34 (0.68--2.67)                        0.40                                                                       
   Panipenem-betamipron      0.78 (0.23--2.56)                        0.68                                                                       
   Piperacillin              0.87 (0.43--1.73)                        0.69                                                                       
   Piperacillin-tazobactam   1.87 (0.91--3.86)                        0.09                                                                       
   Vancomycin                1.16 (0.58--2.31)                        0.66                                                                       
  Surgical ward              1.40 (0.70--2.80)                        0.34                                                                       
  CL-day                     5.60 (1.97--15.94)                       \<0.01[\*](#tfn3-idr-7-331){ref-type="table-fn"}   5.51 (1.94--15.69)      \<0.01[\*](#tfn3-idr-7-331){ref-type="table-fn"}
  Male sex                   0.62 (0.29--1.35)                        0.23                                                                       
  Age \>75 years             0.90 (0.45--1.81)                        0.76                                                                       
  DU ratio                   1.43 (0.72--2.86)                        0.30                                                                       

**Notes:**

*P*\<0.05. DU ratio is defined as number of CL-days/number of patient-days.

**Abbreviations:** AUD, antimicrobial use density; CLABSI, central line-associated bloodstream infection; N/A, not available due to sample deviation; CL-day, days of central line placement; DU, device utilization of the former half as the index study period.
